Ratings Tilray Brands, Inc.

Equities

Market Closed - Nasdaq Other stock markets 21:00:00 10/09/2024 BST			5-day change	1st Jan Change
1.700 ^USD	0.00%		-0.58%	-26.09%

09-09	Tilray Medical Supports Scientific Study on Fibromyalgia With "Positive Outcomes"	MT
09-03	Equities Plunge as Data Show Persistent Manufacturing Contraction	MT

On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
From a short-term investment perspective, the company presents a deteriorated fundamental situation
The company has a poor ESG score according to Refinitiv, which ranks companies by sector.

Growth remains a strong point in this company. In their sales forecast, analysts sound optimistic with regard to sales prospects.
The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.

The company has insufficient levels of profitability.
The valuation of the company is particularly high given the cash flows generated by its activity.
For the past year, analysts have significantly revised downwards their profit estimates.
For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
The group usually releases earnings worse than estimated.

Source: Surperformance

Source: Refinitiv

Add to a list Add to a list 0 selected To use this feature you must be a member Log in Sign up	Composite Valuation	Capi. ($)
TILRAY BRANDS, INC.	-	1.43B
ELI LILLY AND COMPANY		818B
NOVO NORDISK A/S		582B
JOHNSON & JOHNSON		401B
ABBVIE INC.		347B
MERCK & CO., INC.		293B
ASTRAZENECA PLC		258B
ROCHE HOLDING AG		254B
NOVARTIS AG		238B
AMGEN INC.		175B
Average		336.56B
Weighted average by Cap.